Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908Phase 3Recruiting
- Lead sponsor
- ImmunityBio, Inc. (Industry)
- Enrollment
- 507 (estimated)
- Start date
- 1 Oct 2025
- Primary completion
- Sep 2028 (estimated)
- Study completion
- 1 Jan 2029
- Last update posted
- 2 Nov 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 4
Interventions
- N-803 Drug
- Tislelizumab Drug
- Docetaxel Drug
- Prior failed checkpoint inhibitor Drug
Conditions and primary outcome
- NSCLC Stage IV
Primary outcome
Compare Overall Survival between the experimental and control arms (Approximately 12 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06745908.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06745908 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.